Published in J Urol on May 01, 2002
The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol (2008) 1.11
How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? Can Urol Assoc J (2013) 1.09
Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol (2013) 1.03
Twenty Years of PSA: From Prostate Antigen to Tumor Marker. Rev Urol (2007) 0.95
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian J Clin Biochem (2006) 0.78
[Significance of the PSA-concentration for the detection of prostate cancer]. Pathologe (2005) 0.77
The value of an artificial neural network in the decision-making for prostate biopsies. World J Urol (2009) 0.77
Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage? Eur J Med Res (2011) 0.77
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods (2013) 3.63
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology (2008) 2.04
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem (2009) 2.01
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol (2008) 2.00
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology (2003) 1.94
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology (2002) 1.74
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74